Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Greinix, HT; Volc-Platzer, B; Kalhs, P; Fischer, G; Rosenmayr, A; Keil, F; Hönigsmann, H; Knobler, RM.
Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study.
Blood. 2000; 96(7):2426-2431
Doi: 10.1182/blood.V96.7.2426
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Greinix Hildegard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing agent 8-methoxypsoralen and UV-A radiation has been shown to be effective in the treatment of selected diseases mediated by T cells, rejection after solid organ transplantation, and chronic graft-versus-host disease (GVHD). We present 21 patients with a median age of 38 years who developed steroid-refractory acute GVHD grades II to IV after stem cell grafting from sibling or unrelated donors and were referred to extracorporeal photochemotherapy (ECP). Three months after initiation of ECP 60% of patients achieved a complete resolution of GVHD manifestations. Complete responses were obtained in 100% of patients with grade II, 67% of patients with grade III, and 12% of patients with grade IV acute GVHD. Three months after start of ECP complete responses were achieved in 60% of patients with cutaneous, 67% with liver, and none with gut involvement. Adverse events observed during ECP included a decrease in peripheral blood cell counts in the early phase after stem cell transplantation (SCT). Currently, 57% of patients are alive at a median observation time of 25 months after SCT. Probability of survival at 4 years after SCT is 91% in patients with complete response to ECP compared to 11% in patients not responding completely. Our findings suggest that ECP is an effective adjunct therapy for acute steroid-refractory GVHD with cutaneous and liver involvement. However, in patients with acute GVHD grade IV or gut involvement other therapeutic options are warranted.
- Find related publications in this database (using NLM MeSH Indexing)
- Acute Disease -
- Adult -
- Biopsy -
- Drug Resistance -
- Female -
- Gastrointestinal Hemorrhage - etiology Gastrointestinal Hemorrhage - mortality
- Graft vs Host Disease - complications Graft vs Host Disease - drug therapy Graft vs Host Disease - mortality
- Humans -
- Infection - etiology Infection - mortality
- Male -
- Methoxsalen - therapeutic use
- Middle Aged -
- Multiple Organ Failure - etiology Multiple Organ Failure - mortality
- Photopheresis -
- Pilot Projects -
- Skin - pathology
- Skin Diseases - etiology Skin Diseases - pathology
- Steroids - therapeutic use
- Survival Rate -
- Treatment Outcome -
- Ultraviolet Rays -